Below is a detailed analysis of the quarterly data for Vesuvius India Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
For Sales, as of Mar 2025, the value is 482.00 Cr.. The value appears to be declining and may need further review. It has decreased from 509.00 Cr. (Dec 2024) to 482.00 Cr., marking a decrease of 27.00 Cr..
For Expenses, as of Mar 2025, the value is 399.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 427.00 Cr. (Dec 2024) to 399.00 Cr., marking a decrease of 28.00 Cr..
For Operating Profit, as of Mar 2025, the value is 83.00 Cr.. The value appears strong and on an upward trend. It has increased from 82.00 Cr. (Dec 2024) to 83.00 Cr., marking an increase of 1.00 Cr..
For OPM %, as of Mar 2025, the value is 17.00%. The value appears strong and on an upward trend. It has increased from 16.00% (Dec 2024) to 17.00%, marking an increase of 1.00%.
For Other Income, as of Mar 2025, the value is 10.00 Cr.. The value appears strong and on an upward trend. It has increased from 7.00 Cr. (Dec 2024) to 10.00 Cr., marking an increase of 3.00 Cr..
For Interest, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
For Depreciation, as of Mar 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 13.00 Cr..
For Profit before tax, as of Mar 2025, the value is 80.00 Cr.. The value appears strong and on an upward trend. It has increased from 76.00 Cr. (Dec 2024) to 80.00 Cr., marking an increase of 4.00 Cr..
For Tax %, as of Mar 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 22.00% (Dec 2024) to 26.00%, marking an increase of 4.00%.
For Net Profit, as of Mar 2025, the value is 59.00 Cr.. The value appears to be declining and may need further review. It has decreased from 60.00 Cr. (Dec 2024) to 59.00 Cr., marking a decrease of 1.00 Cr..
For EPS in Rs, as of Mar 2025, the value is 2.92. The value appears to be declining and may need further review. It has decreased from 2.95 (Dec 2024) to 2.92, marking a decrease of 0.03.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
×
Quarterly Chart
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 3:30 pm
Metric
Dec 2013
Dec 2014
Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
TTM
Sales
602
652
700
822
911
925
887
792
1,047
1,343
1,603
1,869
1,897
Expenses
489
552
574
670
745
777
766
714
947
1,178
1,314
1,518
1,562
Operating Profit
112
101
126
152
167
148
121
77
100
165
289
350
335
OPM %
19%
15%
18%
18%
18%
16%
14%
10%
10%
12%
18%
19%
18%
Other Income
5
9
10
13
9
23
29
21
20
23
35
48
50
Interest
1
0
1
1
1
1
1
1
1
1
2
4
1
Depreciation
18
19
23
27
30
28
27
26
27
30
36
46
48
Profit before tax
99
90
112
136
145
142
123
72
92
157
285
349
336
Tax %
34%
34%
35%
35%
35%
35%
31%
26%
26%
26%
25%
24%
Net Profit
65
59
74
89
94
93
86
53
68
117
213
265
255
EPS in Rs
3.21
2.91
3.63
4.38
4.65
4.56
4.21
2.61
3.35
5.75
10.49
13.03
12.56
Dividend Payout %
15%
24%
17%
15%
15%
15%
21%
27%
24%
14%
12%
11%
×
Profit & Loss Yearly Chart
YoY Net Profit Growth
Year
YoY Net Profit Growth (%)
Change in YoY Net Profit Growth (%)
No data available for trend analysis.
Growth
Compounded Sales Growth
10 Years:
11%
5 Years:
16%
3 Years:
21%
TTM:
12%
Compounded Profit Growth
10 Years:
16%
5 Years:
24%
3 Years:
55%
TTM:
7%
Stock Price CAGR
10 Years:
23%
5 Years:
43%
3 Years:
70%
1 Year:
1%
Return on Equity
10 Years:
14%
5 Years:
14%
3 Years:
17%
Last Year:
19%
Last Updated: Unknown
No data available for the Balance Sheet data table.
After reviewing the key financial ratios for Vesuvius India Ltd, here is a detailed analysis based on the latest available data and recent trends:
For FaceValue, as of Dec 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Dec 23) which recorded 10.00.
For Basic EPS (Rs.), as of Dec 24, the value is 130.33. This value is within the healthy range. It has increased from 104.92 (Dec 23) to 130.33, marking an increase of 25.41.
For Diluted EPS (Rs.), as of Dec 24, the value is 130.33. This value is within the healthy range. It has increased from 104.92 (Dec 23) to 130.33, marking an increase of 25.41.
For Cash EPS (Rs.), as of Dec 24, the value is 152.89. This value is within the healthy range. It has increased from 122.59 (Dec 23) to 152.89, marking an increase of 30.30.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Dec 24, the value is 704.92. It has increased from 587.95 (Dec 23) to 704.92, marking an increase of 116.97.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Dec 24, the value is 704.92. It has increased from 587.95 (Dec 23) to 704.92, marking an increase of 116.97.
For Dividend / Share (Rs.), as of Dec 24, the value is 14.50. This value exceeds the healthy maximum of 3. It has increased from 12.75 (Dec 23) to 14.50, marking an increase of 1.75.
For Revenue From Operations / Share (Rs.), as of Dec 24, the value is 920.48. It has increased from 789.72 (Dec 23) to 920.48, marking an increase of 130.76.
For PBDIT / Share (Rs.), as of Dec 24, the value is 195.01. This value is within the healthy range. It has increased from 158.50 (Dec 23) to 195.01, marking an increase of 36.51.
For PBIT / Share (Rs.), as of Dec 24, the value is 172.42. This value is within the healthy range. It has increased from 140.80 (Dec 23) to 172.42, marking an increase of 31.62.
For PBT / Share (Rs.), as of Dec 24, the value is 171.84. This value is within the healthy range. It has increased from 140.59 (Dec 23) to 171.84, marking an increase of 31.25.
For Net Profit / Share (Rs.), as of Dec 24, the value is 130.31. This value is within the healthy range. It has increased from 104.90 (Dec 23) to 130.31, marking an increase of 25.41.
For PBDIT Margin (%), as of Dec 24, the value is 21.18. This value is within the healthy range. It has increased from 20.07 (Dec 23) to 21.18, marking an increase of 1.11.
For PBIT Margin (%), as of Dec 24, the value is 18.73. This value is within the healthy range. It has increased from 17.82 (Dec 23) to 18.73, marking an increase of 0.91.
For PBT Margin (%), as of Dec 24, the value is 18.66. This value is within the healthy range. It has increased from 17.80 (Dec 23) to 18.66, marking an increase of 0.86.
For Net Profit Margin (%), as of Dec 24, the value is 14.15. This value exceeds the healthy maximum of 10. It has increased from 13.28 (Dec 23) to 14.15, marking an increase of 0.87.
For Return on Networth / Equity (%), as of Dec 24, the value is 18.48. This value is within the healthy range. It has increased from 17.84 (Dec 23) to 18.48, marking an increase of 0.64.
For Return on Capital Employeed (%), as of Dec 24, the value is 23.79. This value is within the healthy range. It has increased from 23.22 (Dec 23) to 23.79, marking an increase of 0.57.
For Return On Assets (%), as of Dec 24, the value is 14.32. This value is within the healthy range. It has increased from 13.40 (Dec 23) to 14.32, marking an increase of 0.92.
For Asset Turnover Ratio (%), as of Dec 24, the value is 1.09. It has decreased from 1.10 (Dec 23) to 1.09, marking a decrease of 0.01.
For Current Ratio (X), as of Dec 24, the value is 3.12. This value exceeds the healthy maximum of 3. It has increased from 3.10 (Dec 23) to 3.12, marking an increase of 0.02.
For Quick Ratio (X), as of Dec 24, the value is 2.47. This value exceeds the healthy maximum of 2. It has increased from 2.38 (Dec 23) to 2.47, marking an increase of 0.09.
For Inventory Turnover Ratio (X), as of Dec 24, the value is 2.59. This value is below the healthy minimum of 4. It has decreased from 2.64 (Dec 23) to 2.59, marking a decrease of 0.05.
For Dividend Payout Ratio (NP) (%), as of Dec 24, the value is 9.78. This value is below the healthy minimum of 20. It has increased from 7.86 (Dec 23) to 9.78, marking an increase of 1.92.
For Dividend Payout Ratio (CP) (%), as of Dec 24, the value is 8.33. This value is below the healthy minimum of 20. It has increased from 6.72 (Dec 23) to 8.33, marking an increase of 1.61.
For Earning Retention Ratio (%), as of Dec 24, the value is 90.22. This value exceeds the healthy maximum of 70. It has decreased from 92.14 (Dec 23) to 90.22, marking a decrease of 1.92.
For Cash Earning Retention Ratio (%), as of Dec 24, the value is 91.67. This value exceeds the healthy maximum of 70. It has decreased from 93.28 (Dec 23) to 91.67, marking a decrease of 1.61.
For Interest Coverage Ratio (X), as of Dec 24, the value is 335.48. This value is within the healthy range. It has decreased from 748.26 (Dec 23) to 335.48, marking a decrease of 412.78.
For Interest Coverage Ratio (Post Tax) (X), as of Dec 24, the value is 225.17. This value is within the healthy range. It has decreased from 496.21 (Dec 23) to 225.17, marking a decrease of 271.04.
For Enterprise Value (Cr.), as of Dec 24, the value is 8,763.00. It has increased from 6,817.43 (Dec 23) to 8,763.00, marking an increase of 1,945.57.
For EV / Net Operating Revenue (X), as of Dec 24, the value is 4.69. This value exceeds the healthy maximum of 3. It has increased from 4.25 (Dec 23) to 4.69, marking an increase of 0.44.
For EV / EBITDA (X), as of Dec 24, the value is 22.14. This value exceeds the healthy maximum of 15. It has increased from 21.19 (Dec 23) to 22.14, marking an increase of 0.95.
For MarketCap / Net Operating Revenue (X), as of Dec 24, the value is 4.95. This value exceeds the healthy maximum of 3. It has increased from 4.54 (Dec 23) to 4.95, marking an increase of 0.41.
For Retention Ratios (%), as of Dec 24, the value is 90.21. This value exceeds the healthy maximum of 70. It has decreased from 92.13 (Dec 23) to 90.21, marking a decrease of 1.92.
For Price / BV (X), as of Dec 24, the value is 6.46. This value exceeds the healthy maximum of 3. It has increased from 6.10 (Dec 23) to 6.46, marking an increase of 0.36.
For Price / Net Operating Revenue (X), as of Dec 24, the value is 4.95. This value exceeds the healthy maximum of 3. It has increased from 4.54 (Dec 23) to 4.95, marking an increase of 0.41.
For EarningsYield, as of Dec 24, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Dec 23) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
×
Profitability Ratios (%)
Liquidity Ratios
Liquidity Ratios (%)
Interest Coverage Ratios (%)
Valuation Ratios
Fair Value
Fair Value of Vesuvius India Ltd as of July 18, 2025 is: 451.91
Calculation basis:
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.
As of July 18, 2025, Vesuvius India Ltd is Overvalued by 13.09% compared to the current share price 520.00
Intrinsic Value of Vesuvius India Ltd as of July 18, 2025 is: 588.63
Calculation basis:
Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.
This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.
As of July 18, 2025, Vesuvius India Ltd is Undervalued by 13.20% compared to the current share price 520.00
Last 5 Year EPS CAGR: 30.25%
*Investments are subject to market risks
Strength and Weakness
Unable to fetch valid data for stock valuation.
Stock Analysis
Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vesuvius India Ltd:
Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
ROE%: 18.48% (Industry Average ROE: 13.51%)
ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
Stock P/E: 41.4 (Industry average Stock P/E: 37)
Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
Total Debt / Equity: 0
Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions. Stock Rating:
About the Company - Qualitative Analysis
Vesuvius India Ltd. is a Public Limited Listed company incorporated on 06/09/1991 and has its registered office in the State of West Bengal, India. Company's Corporate Identification Number(CIN) is L26933WB1991PLC052968 and registration number is 052968. Currently Company is involved in the business activities of Manufacture of refractory products. Company's Total Operating Revenue is Rs. 1868.57 Cr. and Equity Capital is Rs. 20.30 Cr. for the Year ended 31/12/2024.
FAQ: Stock data is invalid or not in the correct format.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Vesuvius India Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
